For the past few months many articles have appeared in relation to the different challenges that Brazil has in terms of prosecuting patents. These challenges have been present in the country for quite a long time and have been consistently mentioned by the Office of the United States Trade Representative. read more
The 2017 Special 301 Report mentioned the concern for the long delays in the examination of both patent and trademark applications, with a reported average pendency of nearly two and a half years for trademarks and almost 11 years for patents, as well as for the National Sanitary Regulatory Agency's (ANVISA) duplicate review of pharmaceutical patent applications.Brazil is currently undergoing a process of addressing these issues. This article aims at providing an overall picture of where the country is and what can be expected.
The main challenges are summarized in the newsletter which can be downloaded by clicking the link bellow, "
Complete bulletin in PDF".